The Pulse of Biomanufacturing: Economic Growth and Trends in the Bay Area

Host Jared Asch interviews manufacturing engineer Gregory Theyel about the Bay Area’s biomedical and life science ecosystem and why it matters for long-term regional economic stability. Thao frames manufacturing as a “big M” strategy that bridges ideas and public needs, and defines biomedical as an umbrella spanning biotech, pharmaceuticals, medtech, cell and gene therapies, digital health, and genomics. He describes headwinds in 2022–23 from reduced government grants and constrained capital, followed by a rebound driven by AI, efficiency gains, and personalized medicine, with robust investment through 2025–26. Thao cites Bay Area advantages: leading research at Stanford, UC Berkeley, and UCSF, strong spinout culture, major venture funding, deep talent, and a tolerance for failure. He explains why some manufacturing remains local (feedback loops, individualized therapies) and why reshoring/nearshoring have accelerated (the innovation cycle and geopolitical instability). He outlines what cities must provide—specialized facilities, trained workforce, and efficient permitting—highlights clustering in South San Francisco, Berkeley/Emeryville, and Fremont, and stresses demand-side healthcare partners, pilots, and mapping supply networks to help firms understand their role in the regional ecosystem.